The impact of supraventricular ectopic complexes in different age groups and risk of recurrent atrial fibrillation after antiarrhythmic medication or catheter ablation
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
The impact of supraventricular ectopic complexes in different age groups and risk of recurrent atrial fibrillation after antiarrhythmic medication or catheter ablation. / Alhede, Christina; Lauridsen, Trine K.; Johannessen, Arne; Dixen, Ulrik; Jensen, Jan S.; Raatikainen, Pekka; Hindricks, Gerhard; Walfridsson, Haakan; Kongstad, Ole; Pehrson, Steen; Englund, Anders; Hartikainen, Juha; Hansen, Peter S.; Nielsen, Jens C.; Jons, Christian.
I: International Journal of Cardiology, Bind 250, 2018, s. 122-127.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - The impact of supraventricular ectopic complexes in different age groups and risk of recurrent atrial fibrillation after antiarrhythmic medication or catheter ablation
AU - Alhede, Christina
AU - Lauridsen, Trine K.
AU - Johannessen, Arne
AU - Dixen, Ulrik
AU - Jensen, Jan S.
AU - Raatikainen, Pekka
AU - Hindricks, Gerhard
AU - Walfridsson, Haakan
AU - Kongstad, Ole
AU - Pehrson, Steen
AU - Englund, Anders
AU - Hartikainen, Juha
AU - Hansen, Peter S.
AU - Nielsen, Jens C.
AU - Jons, Christian
PY - 2018
Y1 - 2018
N2 - Introduction Supraventricular ectopic complexes (SVEC) are known risk factors of recurrent atrial fibrillation (AF). However, the impact of SVEC in different age groups is unknown. We aimed to investigate the risk of AF recurrence with higher SVEC burden in patients ± 57 years, respectively, after treatment with antiarrhythmic medication (AAD) or catheter ablation (CA). Methods In total, 260 patients with LVEF > 40% and age ≤ 70 years were randomized to AAD (N = 132) or CA (N = 128) as first-line treatment for paroxysmal AF. All patients underwent 7-day Holter monitoring at baseline, and after 3, 6, 12, 18 and 24 months and were categorized according to median age ± 57 years. We used multivariate Cox regression analyses and we defined high SVEC burden at 3 months of follow-up as the upper 75th percentile > 195 SVEC/day. AF recurrence was defined as AF ≥ 1 min, AF-related cardioversion or hospitalization. Results Age > 57 years were significantly associated with higher AF recurrence rate after CA (58% vs 36%, p = 0.02). After CA, we observed a higher SVEC burden during follow-up in patients > 57 years which was not observed in the younger age group treated with CA (p = 0.006). High SVEC burden at 3 months after CA was associated with AF recurrence in older patients but not in younger patients (> 57 years: HR 3.4 [1.4–7.9], p = 0.005). We did not find any age-related differences after AAD. Conclusion We found that younger and older patients respond differently to CA and that SVEC burden was only associated with AF recurrence in older patients.
AB - Introduction Supraventricular ectopic complexes (SVEC) are known risk factors of recurrent atrial fibrillation (AF). However, the impact of SVEC in different age groups is unknown. We aimed to investigate the risk of AF recurrence with higher SVEC burden in patients ± 57 years, respectively, after treatment with antiarrhythmic medication (AAD) or catheter ablation (CA). Methods In total, 260 patients with LVEF > 40% and age ≤ 70 years were randomized to AAD (N = 132) or CA (N = 128) as first-line treatment for paroxysmal AF. All patients underwent 7-day Holter monitoring at baseline, and after 3, 6, 12, 18 and 24 months and were categorized according to median age ± 57 years. We used multivariate Cox regression analyses and we defined high SVEC burden at 3 months of follow-up as the upper 75th percentile > 195 SVEC/day. AF recurrence was defined as AF ≥ 1 min, AF-related cardioversion or hospitalization. Results Age > 57 years were significantly associated with higher AF recurrence rate after CA (58% vs 36%, p = 0.02). After CA, we observed a higher SVEC burden during follow-up in patients > 57 years which was not observed in the younger age group treated with CA (p = 0.006). High SVEC burden at 3 months after CA was associated with AF recurrence in older patients but not in younger patients (> 57 years: HR 3.4 [1.4–7.9], p = 0.005). We did not find any age-related differences after AAD. Conclusion We found that younger and older patients respond differently to CA and that SVEC burden was only associated with AF recurrence in older patients.
KW - Age
KW - Arrhythmia
KW - Premature ectopic beats
KW - Recurrence
KW - Treatment
U2 - 10.1016/j.ijcard.2017.09.208
DO - 10.1016/j.ijcard.2017.09.208
M3 - Journal article
C2 - 29050922
AN - SCOPUS:85031489505
VL - 250
SP - 122
EP - 127
JO - International Journal of Cardiology
JF - International Journal of Cardiology
SN - 0167-5273
ER -
ID: 214758678